Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing a DMT for Parkinson’s.

The house lights pop on at London’s 250-cap Camden Assembly, and the crush around the battered merch table is instant. A laminated QR code leans against a stack of fresh 7-inches; one scan opens the ...